Business
Orum Therapeutics to Present New Preclinical Data on ORM-1153, a CD123-Targeting Degrader Antibody Conjugate, at the AACR Annual Meeting 2026
BOSTON & DAEJEON, South Korea, March 17, 2026--Orum Therapeutics to Present New Preclinical Data on ORM-1153, a CD123-Targeting Degrader Antibody Conjugate, at the AACR Annual Meeting 2026
About this update from Orum Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":228,"url":"https://media.zenfs.com/en/business-wire.com/a795070b97d136a2a66171d8a0b1f7ee"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xkc1jznBGdk0dLtkfygQfQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ1NjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/a795070b97d136a2a66171d8a0b1f7ee","width":480,"height":228}},"lazy":false},{"type":"text","content":"BOSTON & DAEJEON, South Korea, March 17, 2026--(BUSINESS WIRE)--Orum Therapeutics ("Orum" or the "Company") (KRX: 475830), a biotechnology company pioneering the field of degrader antibody conjugates (DACs), today announced that new preclinical data on ORM-1153, a CD123-targeting DAC designed to selectively deliver a proprietary GSPT1-degrading payload for the treatment of acute myeloid leukemia (AML), will be presented at the American Association for Cancer Research® (AACR) Annual Meeting 2026, taking place April 17-22 in San Diego.","length":563,"tagName":"p"},{"type":"text","content":"Orum’s two posters on ORM-1153 will highlight preclinical efficacy, pharmacology, and non-human primate safety findings that support advancement toward clinical development in AML.","length":180,"tagName":"p"},{"type":"text","content":""The data being presented at AACR reflect continued progress for ORM-1153 and Orum’s Dual-Precision TPD²® approach," said Sung Joo (SJ) Lee, Ph.D., Founder and CEO of Orum. "These preclinical data, including repeat-dose non-human primate studies, support advancement toward clinical development and underscore the potential of our approach to expand the therapeutic window beyond conventional cytotoxic antibody-drug conjugates."","length":449,"tagName":"p"},{"type":"text","content":"Orum’s AACR 2026 Presentation DetailsBoth posters will be presented on Monday, April 20, from 9 am to 12 pm PDT.","length":113,"tagName":"p"},{"type":"text","content":"ORM-1153: A Novel CD123-Targeting Degrader Antibody Conjugate with Proprietary GSPT1 Degrading Payload for the Treatment of Acute Myeloid LeukemiaSession Category: Experimental and Molecular TherapeuticsSession Title: Antibody-Drug Conjugates and Linker Engineering 2Location: Poster Section 13Poster Board Number: 7Poster Number: 1710"...